Related Experiment Videos
Primary lymphoma of bone
Kuauhyama Luna-Ortiz1, Eduardo Cervera-Ceballos, Hugo Dominguez-Malagon
1Department of Surgical Oncology, Instituto Nacional de Cancerología, Mexico. kuauhyama@starmedia.com
Summary
Primary lymphoma of bone (PLB) is rare, accounting for 1.3% of lymphomas. Anthracycline chemotherapy and radiotherapy offer the best treatment outcomes for this condition.
Area of Science:
- Oncology
- Hematology
- Pathology
Background:
- Primary lymphoma of bone (PLB) is an uncommon neoplastic proliferation of lymphoid cells arising within bone tissue.
- It represents a small fraction of all lymphoma cases, necessitating specific diagnostic and management strategies.
Purpose of the Study:
- To review the clinical presentation, management, and outcomes of primary lymphoma of bone (PLB) cases.
- To identify prognostic factors influencing patient survival and treatment response.
Main Methods:
- Retrospective analysis of 8 patients diagnosed with primary lymphoma of bone (stage IE) between 1972 and 1999.
- Histopathological diagnosis using Working Formulation (WF) criteria, re-evaluated with current World Health Organization (WHO) guidelines.
- Treatment modalities included sequential chemotherapy and radiotherapy, chemotherapy alone, or radiotherapy alone.
Main Results:
- Diffuse large B-cell lymphoma was the most common histological subtype.
- Sequential anthracycline-based chemotherapy and radiotherapy resulted in complete response in 5 out of 8 patients.
- Tumor localization and patient's functional status (Karnofsky score) were identified as significant prognostic indicators.
Conclusions:
- Primary lymphoma of bone (PLB) remains a rare entity, constituting 1.3% of lymphomas in this series.
- Combined anthracycline-based chemotherapy and radiotherapy represent the primary therapeutic approach.
- Early functional status and tumor site are critical prognostic factors for patients with PLB.